Last updated on August 2018

Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)


Brief description of study

This is a safety, efficacy, and pharmacokinetics study of MK-7684 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation phase. Part B is a dose confirmation phase to estimate the recommended Phase 2 dose (RPTD) for MK-7684 monotherapy or in combination with pembrolizumab. The anti-tumor activity of MK-7684 when used as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors will be evaluated in Part B in a non-randomized study design. Part B will also evaluate 2 doses of MK-7684 in combination with pembrolizumab in participants with programmed death 1 (PD-1) treatment nave cancer using a 1:1 randomized study design. The primary hypothesis is that MK-7684 administered as monotherapy or in combination with pembrolizumab is safe when administered at the RPTD.

Clinical Study Identifier: NCT02964013

Contact Investigators or Research Sites near you

Start Over

Toll Free Number

Call for Information (Investigational Site 0013)
Gilbert, AZ United States
0.47miles
  Connect »